Litigation

Recent Posts

N.J. Risperdal Jury Finds Diabetes Warning Lacking, But Drug Didn't Cause Disease
Posted on 17 Feb 2012 by Tom Moylan

NEW BRUNSWICK, N.J. - (Mealey's) A Risperdal personal injury trial ended Feb. 16 in a defense verdict for Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc. after a New Jersey state court jury found that Janssen failed to warn about the... Read More

AstraZeneca Pays States $68.5M For Off-Label Marketing Of Seroquel Antipsychotic
Posted on 11 Mar 2011 by Tom Moylan

TRENTON, N.J. - (Mealey's) AstraZeneca Pharmaceuticals L.P. and AstraZeneca L.P. on March 10 agreed to pay $68.5 million to 37 states and the District of Columbia to resolve allegations in a New Jersey state court lawsuit that it marketed its atypical... Read More

AstraZeneca Settles Nearly 4,000 Seroquel Injury Claims; Terms Confidential
Posted on 30 Jul 2010 by Tom Moylan

LONDON - (Mealey's) AstraZeneca PLC said July 29 that it has agreed in principle to settle with nearly 4,000 Seroquel product liability plaintiffs. The company said settlement terms are confidential. In notes to its second-quarter financial... Read More

AstraZeneca Agrees To Settle 17,500 Seroquel Cases For $198 Million
Posted on 9 Aug 2010 by Tom Moylan

WILMINGTON, Del. — AstraZeneca announced Aug. 9 that it has reached agreements in principle to settle about 17,500 Seroquel claims in the United States for about $198 million. “The specific terms of the agreements, which are the result... Read More

AstraZeneca Pays $198M To Settle Seroquel Lawsuits
Posted on 9 Aug 2010 by LexisNexis Litigation Resource Community Staff

LONDON - (AP) AstraZeneca PLC says it has paid around $198 million to settle U.S. lawsuits over its antipsychotic drug Seroquel. Full version available to lexis.com subscriber . Read More

AstraZeneca Paying $68.5 Million In Seroquel Settlement
Posted on 12 Mar 2011 by LexisNexis Litigation Resource Community Staff

WASHINGTON, D.C. - (AP) AstraZeneca will pay $68.5 million as part of a multistate settlement over allegations that the drug developer promoted its blockbuster psychiatric drug Seroquel for insomnia, Alzheimer's and other unapproved uses. The New... Read More

AstraZeneca Wins Patent Dispute Over Crestor
Posted on 30 Jun 2010 by LexisNexis Litigation Resource Community Staff

NEW YORK - (AP) AstraZeneca Plc said Tuesday it won a patent challenge brought against its blockbuster cholesterol drug Crestor by generic drug developers. The U.S. District Court in Delaware ruled that a key patent on the company's third best-selling... Read More

AstraZeneca Settles Patent Litigation With Handa
Posted on 4 Oct 2011 by LexisNexis Litigation Resource Community Staff

LONDON - (AP) Drug maker AstraZeneca says it has reached an agreement with a U.S. company to settle patent infringement litigation. AstraZeneca said Friday that Handa Pharmaceuticals of Fremont, California had accepted that AstraZeneca had valid patents... Read More

Wisconsin To Get $4 Million In Multistate Drug Lawsuit
Posted on 12 May 2010 by LexisNexis Litigation Resource Community Staff

MADISON Wis. – (AP) Attorney General J.B. Van Hollen said Tuesday that Wisconsin will get more than $4 million in a multistate settlement with drug manufacturer AstraZeneca. The drug maker allegedly marketed the anti-psychotic drug Seroquel for... Read More